Biosimilars

Biosimilars are biopharmaceuticals which are highly comparable to an approved originator drug in terms of quality, safety, and efficacy and can be used to treat the same indications. They offer a cost-efficient alternative to a reference medical product, reduce the countries' health care costs, and make life-saving medicine affordable for the general population.

We have developed a broad portfolio of cell lines and processes for biosimilar manufacturing. Our product portfolio which is constantly being improved and extended comprises over 45 biopharmaceuticals such as recombinant proteins, monoclonal antibodies, and fusion proteins.

 

Eukaryotic Expression

Proteins derived from our eukaryotic expression systems

 

 

Prokaryotic Expression

Proteins derived from our prokaryotic expression systems

Our complete ready-to-go biosimilar processes as well as products in different development stages can be found in the tables below.

Eukaryotic Expression

Recombinant Proteins

Recombinant Proteins

EGX Project Molecule Reference
Product		 Main
Indication		 Status at EUGENEX Status at
Client
Cell Line USP DSP
EGX-EP01 Epoetin α
(EPO)		 Epogen,
Eprex		 Anemia on Market
EGX-EP02 Darbepoetin α
(DPO)		 Aranesp Anemia on Market
EGX-EP03 Interferon β-1a
(INFβ)		 Avonex,
Rebif 		Multiple
Sclerosis
EGX-EP04 Follicle
Stimulating
Hormone
(FSH)		 Gonal-F,
Puregon		 Infertility on Market
EGX-EP05 Human Chorio-
gonadotropin
(hCG)		 Ovidrel Infertility on Market
EGX-EP06 Human
Luteinizing
Hormone
(hLH)		 Luveris Infertility Clinical
Trial
EGX-EP07 Urokinase
(uPA)		 Abbokinase Thrombolysis
EGX-EP08 Alteplase
(tPA)		 Actilyse,
Activase		 Thrombolysis
EGX-EP09 Tenecteplase
(TNK-tPA)		 Metalyse Thrombolysis Clinical
Trial
EGX-EP10 Factor VIIa
(FVIIa)		 Novoseven Hemophilia
EGX-EP11 Faktor VIII
(FVIIII)		 Recombinate Hemophilia
EGX-EP12 β-Glucocere-
brosidase
(GCaseβ)		 Cerezyme Morbus
Gaucher
EGX-EP13 Dornase α
(DNAse I)		 Pulmozyme Cystic Fibrosis
EGX-EP14 Thrombin
(FIIa)		 - Hemostasis
EGX-EP15 Corifolitropin
alpha		 Elonva Infertility
EGX-EP16 Galsulfase Naglazyme Mucopoly-
saccharidosis
VI

 Antibodies

Antibodies

EGX Project Molecule
(Target)		 Reference
Product		 Main
Indications		 Status at EUGENEX Status at
Client
Cell Line USP DSP
EGX-EA01 Adalimumab
(TNFα)		 Humira Rheumatoid
Arthritis,
Psoriasis		 on Market
EGX-EA02 Rituximab
(CD20)		 Rituxan Lymphoma,
Rheumatoid
Arthritis		 on Market
EGX-EA03 Trastuzumab
(HER2)		 Herceptin Breast Cancer, Gastric Cancer on Market
EGX-EA04 Bevacizumab
(VEGF)		 Avastin Lung Cancer,
Colorectal
Cancer		 on Market
EGX-EA05 Cetuximab
(EGF-
Receptor)		 Erbitux Colorectal
Cancer,
Head &
Neck Cancer
EGX-EA06 Omalizumab
(IgE)		 Xolair Persistent
Allergic
Asthma,
Asthma
EGX-EA07 Denosumab
(RANKL)		 Prolia Osteoporosis, Chemotherapie Induced Bone
Loss 		Clinical
Trial
EGX-EA08 Tocilizumab
(IL6-Receptor)		 Actemra COVID-19,
Rheumatoid
Arthritis,
Castleman's
Disease		 on Market
EGX-EA09 Ipilimumab
(CTLA-4)		 Yervoy Lung/Renal
Cancer,
Melanoma
EGX-EA10 Panitumumab
(EGF-Receptor)		 Vectibix Colorectal
Cancer
EGX-EA11 Pertuzumab
(HER2)		 Perjeta Breast Cancer
EGX-EA12 Eculizumab
(Complement
component 5)		 Soliris Hemoglobin-
uria,
Myasthenia
Gravis
EGX-EA13 Natalizumab
(Integrin α)		 Tysabri Multiple
Sclerosis,
Crohn‘s
Disease
EGX-EA14 Infliximab
(TNFα)		 Remicade Rheumatoid
Arthritis,
Psoriasis
EGX-EA15 Pembrolizumab
(PD1-
Receptor)		 Keytruda Lung/Renal
Cancer,
Hodgkin‘s
Disease
EGX-EA16 Nivolumab
(PD1-
Receptor)		 Opdivo Melanoma,
Lung/Renal
Cancer
EGX-EA17 Atezolizumab
(PD-L1)		 Tecentriq Urothelial/
Breast/Lung
Cancer
EGX-EA18 Daratumumab
(CD38)		 Darzalex Multiple
Myeloma
EGX-EA19 Guselkumab
(IL-23)		 Tremfya Psoriasis
EGX-EA20 Obinutuzumab
(CD20)		 Gazyva Chronic
Lymphocytic
Leukemia

Fusion Protein

Fusion Proteins

EGX Project Molecule
(Target)		 Reference
Product		 Main
Indications		 Status at EUGENEX Status at
Client
Cell Line USP DSP
EGX-EF01 Etanercept
(TNFα/β)		 Enbrel Chronical
Arthritis,
Psoriasis		 Clinical
Trial
EGX-EF02 Abatacept
(CD80, CD86)		 Orencia Rheumatoid
Arthritis
EGX-EF03 Belatacept
(CD80, CD86)		 Nulojix Kidney
Transplantation
EGX-EF04 Dulaglutid
(GLP-1-
Receptor)		 Trulicity Diabetes
mellitus Type II
 

 

Prokaryotic Expression

Prokaryotic Proteins

Growth Factors, Hormones, Cytokines

EGX Project Molecule Reference
Product		 Main
Indication		 Status at EUGENEX Status
at Client
Cell Line USP DSP
EGX-PP01 Becaplermin
(PDGF-BB)		 Regranex Diabetic
Neuropathic
Ulcers
EGX-PP02 PDGF-AB - Diabetic
Neuropathic
Ulcers		 Clinical
Trial
EGX-PP03 TGFβ-3 - Wound Healing
EGX-PP04 Dibotermin α
(BMP-2)		 Inductos Degenerative
Disc Disease
EGX-PP05 Eptotermin α
(BMP-7)		 Osigraft Fractures
EGX-PP06 Filgrastim
(G-CSF)		 Neupogen Neutropenia
EGX-PP07 Interleukin-2 Proleukin Metastatic
Renal Cell
Carcinoma
EGX-PP08 Sargramostim
(GM-CSF)		 Leukine
 Neutropenia
EGX-PP09 Interferon-α2 Roferon-A Leukemia
EGX-PP10 Interferon-γ-1b Actimmune Chronic
Granulomatous
Disease
EGX-PP11 Somatropin
(Growth
Hormone)		 Humatrope Growth
Hormone
Deficiency

You are interested in individual steps of our development chain or your protein of interest is not in the table?

Check out our Services.

For more detailed information please contact: info@eugenex.com